Nuevas perspectivas en el tratamiento del cáncer de pulmón no microcítico: farmacogenómica

the most commonly used chemotherapy strategy in advanced non-small cell lung cancer (nsclc) today is the combination of two drugs, mainly cisplatin with another drug (gemcitabine, vinorelbine, taxanes, irinotecan). in the last decade attempts have been made to overcome chemotherapy resistance without benefit in outcome. there is a "plateau" in the results which seems unable to progress beyond the frontier of 8-10 months of median survival. at present, research in cancer survival is focused on translational pharmacogenomics, with the goal of providing individualized ct based on different genetic traits, such a polymorphisms, gen mutation and overexpresion of drug target gene transcripts, and several molecular assays can been used to tailor chemotherapy in the care of lung cancer patients. accumulated evidence indicates that many genetic markers are related to chemotherapy resistance. one of the most important goals in translational research is to investigate the clinical use of the dna repair pathways. several genes such as ercc1, xpd polymorphisms. rrm1, bcra1, etc are related to cisplatin and other drugs resistance.